Gillian McGovern, Editor

The treatment's approval was supported by positive evidence from the phase 1/2 CHORD clinical trial.

Ecopipam reduces Tourette tic relapse risk by approximately 50% with durable control and no movement-related adverse effects.

Phase 3 data show quarterly cemdisiran injections improve gMG symptoms, either and matches or outperforms all study end points compared to combination therapy.

Phase 3 METEOROID shows IL-6 blocker satralizumab cuts MOGAD relapses 68%, with rapid onset and placebo-like safety.

The research highlights the influence of hormonal changes on treatment selection and the need for more tailored, life stage–specific care.

The data, which were presented at the AAN 2026 Annual Meeting, support the agents’ neurological safety, but longer follow-ups and dedicated outcome trials are needed to confirm these findings.

Phase 3 SYMPHONY clinical trial data show reboxetine eases narcolepsy type 1 symptoms, improving functional impairment due to excessive daytime sleepiness (EDS) as well as mood symptoms.

McCreary and Dudley emphasize the role of pharmacists when optimizing antimicrobial use, supporting patient care across diverse settings, and driving education, research, and policy.

Experts describe how infectious disease pharmacists drive antimicrobial stewardship, tackle resistance, and shape global training as SIDP marks 35 years.

Anthony Blaszczyk, PhD, explains the intricacy of CGT manufacturing demands, best practices, and how USP is supporting developers.

The indication is to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic symptoms.

Peer review strengthens the quality, clarity, and credibility of manuscripts while providing professional and educational benefits to students in the process.

This is the second complete response letter the manufacturer has received for this treatment regimen.

Pharmacists guide women through updated menopause hormone therapy labels, rising demand, patch shortages, and personalized risk-benefit counseling.

The approval is supported by clinical data from the ATTAIN-1 and ATTAIN-2 trials.

Martinez Sanchez describes early signs of Parkinson disease, how treatment adapts, and how ambulatory pharmacists fine-tune treatment, adherence, and hope amid new therapies.

Eduardo Martinez Sanchez, PharmD, CPh, BCPS, BCACP, discusses key counseling points, the importance of individualizing disease management, and promising therapies to keep an eye on.

The safety and effectiveness of marne-cel were established in an open-label, single-arm, multicenter phase 1/2 clinical trial.

Insulin icodec-abae injection becomes the first and only once-weekly basal insulin option, offering personalized care for adults with type 2 diabetes (T2D).

A panel of neurology pharmacy specialists discusses the expanding clinical role of pharmacists in multiple sclerosis care.

The indication is for patients who have received 1 to 3 prior systemic treatment regimens, of which at least 1 includes bevacizumab.

Pharmacists play a key role in modern obesity care through education, access support, and collaboration.

Pharmacists guide HR+ breast cancer CDK4/6 therapy, tackling interactions, costs, and toxicity monitoring, and applying new clinical trial insights.

CDK4/6 inhibitor therapies must by tailored by comorbidities, interactions, cost, and coordinated labs with pharmacist expertise to support high-risk patients.

The FDA approval of the Wegovy pill offers a new, effective GLP-1 option for weight management, with pharmacists playing a key role in patient counseling and adherence support.

The expanded indication is supported by findings from the phase 3 TRANSCEND clinical trial.

RUNX1 in microglia helps predict opioid pain relief, higher morphine needs, and withdrawal severity—pointing to genetic screening and safer, personalized pain management.

Although the rates of gabapentin use without a prescription were nearly double those of prescribed use, the trends are decreasing over time.

MS requires interdisciplinary collaboration, including pharmacists who can support patients throughout disease management.

The experts express their concerns that current ACIP decisions and guidelines are not backed by "pure science."